Several groundbreaking treatments are transforming blood sugar management, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide being highlighted leading choices. Retatrutide, a dual GIP and GLP-1 site activator, exhibits remarkable fat reduction coupled with enhanced blood sugar control. Cagrillintide, a GLP-1 activator, is presently in r